Exosomes are extracellular vesicles that contain diverse components such as genetic materials, proteins, and lipids. Owing to their distinct derivation and tissue specificity, exosomes act as double-edged swords during the development of neoplasms. On the one hand, tumor-derived exosomes can modulate the immune system during tumorigenesis by regulating inflammatory cell infiltration and oxidative stress and by promoting epithelial-to-mesenchymal transition and immune-induced tumor dormancy. On the other hand, components of specific immune cell-derived exosomes may contribute to the efficacy of antitumor immunotherapy. In this review, we demonstrate the pivotal role of exosomes in the triangular relationship in the tumor microenvironment between the tumor, inflammation, and immunity, which may provide potential strategies for tumor immunotherapy at genetic and cellular levels.

1. Introduction

Exosomes are vesicles that contain genetic materials, lipids, and functional proteins, and exosomes secreted by cancer and immune cells contain cell-specific content. Owing to their widespread and stable existence in biological fluids, exosomes may act as useful biomarkers for detecting the progression of cancers [1]. Intriguingly, exosomes exert bidirectional effects on cancers as a result of their distinct origins and heterogeneity. For example, some tumor-derived exosomes (TDEs) act as tumor growth stimulators, activating the epithelial-to-mesenchymal transition (EMT) and tumor dormancy during cancer proliferation, invasion, and metastasis, whereas other exosomes that originate from specific immune cells act as inhibitors that interfere with cancer growth [2]. In addition, many studies have demonstrated the significance of inflammation in the initiation and development of tumors, and it has been shown that exosomes can affect the progression of inflammation in the tumor environment by initiating inflammatory pathways, activating neutrophils, and regulating oxidative stress. This review discusses the latest research on the functions of exosomes in the triangular relationship between the tumor, inflammation, and immunity in the tumor environment and provides a basis for the potential use of exosomes as vectors in tumor gene therapy and tumor immunotherapy.

2. Exosomes

2.1. Exosomes and Their Biological Characteristics. Extracellular vesicles (EVs) consist of three main subtypes based on their biogenesis: exosomes, microvesicles, and apoptotic bodies [3, 4]. Exosomes are vesicles 40–200 nm in diameter marked by tetraspanins, Alix, and TSG101. Microvesicles are around 200-2000 nm in size and are marked by integrins, selectins, and CD40. Apoptotic bodies are around 500-2000 nm in size and are marked by phosphatidylserines and genomic DNA [5]. Exosomes, which were first identified in sheep reticulocytes in 1985 [6], are double-layered lipid membrane-enclosed vesicles that are secreted by almost all viable cells under both normal and pathological conditions and are extensively present in body fluids, intercellular...
spaces, and tissues [7]. Exosomes contain diverse proteins, lipids, and nucleic acids, such as microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs). There are two types of proteins present in exosomes. The first type, which exists in most exosomes and can function as a marker, includes heat-shock proteins (HSPs), transmembrane 4 superfamily proteins, membrane transport proteins, and fusion proteins [8]. The second type, which is cell-specific and has heterogeneous functions, includes major histocompatibility complex II (MHCII) and fas ligand (FasL), which are present in exosomes from lymphoblastoid cells and induce apoptosis in CD4+ T cells [9]. Exosomes are rich in cholesterol, glycosphingolipids, ether lipids, and phosphatidylserine, which participate in both biogenesis and structural maintenance [10–12]. The first release of the exosome database included 58,330 circRNAs, 15,501 lncRNAs, and 18,333 miRNAs, which suggests a sophisticated genetic control system [13]. These functional RNAs can affect biological activities and modulate cellular events such as cell proliferation, apoptosis, differentiation, and immunoregulation [14–16].

2.2. Exosomes and Intercellular Communication. Exosomes participate in intercellular communication. Tumor-derived exosomal lncRNAs have been implicated as signaling mediators that coordinate the functions of neighboring tumor cells. Interestingly, some exosomal RNAs from donor cells can function in recipient cells and are called “exosomal shuttle RNAs,” suggesting a role in genetic exchange between cells [17]. For example, after stimulation with arsenite, exosomes derived from hepatic epithelial cells can transfer circRNA_100284 to surrounding cells, which increases the expression of enhancer zeste homolog 2 (EZH2) and cyclin-D1 and subsequently promotes the G1/S transition [18]. This finding demonstrates the oncogenic capacity of exosomes. Through intercellular communication, changes in an individual cell may influence the course of tumor proliferation and metastasis on a macroscale. In fact, in epithelial ovarian cancer, tumor-secreted exosomes transfer miR-99a-5p to adjacent human peritoneal mesothelial cells (HPMCs), resulting in increased levels of fibronectin and vitronectin, extracellular matrix components that are closely associated with tumor invasion [19].

2.3. Exosomes and Inflammation. Another vital function of exosomes that is related to disease progression is the modulation of inflammation [20, 21]. Exosomes can promote or inhibit the development of inflammation. Hypoxia-induced delivery of miR-23a from exosomes secreted by tubular epithelial cells was shown to promote macrophage activation and trigger tubulointerstitial inflammation [22]. Similarly, miR-130-5p and miR-142-3p from dendritic cell- (DC-) released exosomes can be transferred to regulatory T cells (Tregs), resulting in an increase in interleukin 10 (IL-10) expression and a decrease in IL-6 expression [23]. Choroid plexus epithelial cells can release exosomes that contain miR-146a and miR-155, which upregulate the expression of inflammatory cytokines in astrocytes and microglia [24]. Another type of exosome exhibits protective effects against inflammation-related diseases [25]. In endometriosis, exosomal miR-138 can protect against inflammation by decreasing the expression level of nuclear factor-xB (NF-xB), a transcription factor that regulates inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and IL-18 [26]. In addition, a study showed that exosomes secreted by bone marrow mesenchymal stem cells (BMSCs) can attenuate inflammatory changes in a rat model of experimental autoimmune encephalomyelitis by modulating microglial polarization and maintaining the balance between M2-related and M1-related cytokines [27]. Another study revealed that exosomal miR-181c suppressed Toll-like receptor 4 (TLR-4) expression and subsequently lowered TNF-α and IL-1β levels in burn-induced inflammation [28]. Treg-derived exosomes containing miR-Let-7d affected T helper cell 1 (Th1) cell growth and inhibited IFN-γ secretion to inhibit inflammation [29]. Exosomal miR-155 from bone marrow cells (BMCs) was shown to enhance the innate immune response in chronic inflammation by increasing TNF-α levels [30]. These findings provide a basis for investigating the role of inflammation in the tumor microenvironment, as well as the possibility of utilizing exosomes as a carrier to attenuate inflammation and restore impaired immune responses in cancer.

3. The Function of Exosomes in the Tumor Microenvironment and Metabolism

3.1. Exosomes Are Involved in Immune Activities during Tumorigenesis. Tumor occurrence is strongly correlated with a failure in immune surveillance, and surprisingly, the translocation of tumor-derived exosomes may assist in immune escape by interfering with cellular events, such as immune cell differentiation and cytokine secretion. One study showed that exogenous circRNAs activate the expression of retinoic-acid-inducible gene-I (RIG-I) and initiate innate immunity [31]. This study clearly demonstrated that foreign genes could affect the endogenous genes in cells and induce an immune reaction. Zhou et al. showed that the melanoma-derived exosomal miRNA-Rab27a could be taken up by CD4+ T cells and may accelerate mitochondrial apoptosis and upregulate the expression of B-cell lymphoma-2 (BCL-2) and B-cell lymphoma-extra large (BCL-xL), which are antiapoptotic proteins [32] (Figure 1). This result demonstrates the interaction between tumor cells and immune cells. This finding is not unique, and other studies have reported similar results. For example, Ning et al. showed that exosomes from lung carcinoma or breast cancer cells could block the differentiation of CD4+IFN-γ+ Th1 cells, inhibit the maturation and migration of DCs, and induce apoptosis to promote the immunosuppressive effect of DCs [33]. Head and neck cancer cell- (HNCC-) derived exosomes affect CD8+ T cells by inducing a loss of CD27/CD28, accompanied by decreased levels of the antitumor cytokine IFN-γ [34] (Figure 1). miR-29a-3p and miR-21-5p in tumor-related macrophage-derived exosomes inhibit the STAT3 signaling pathway and increase the Treg/T helper cell ratio 17 (Th17) ratio in epithelial ovarian cancer, which may lead to poor patient outcomes [35]. Human hepatocellular carcinoma- (HCC-) derived exosomes containing high mobility group box 1
(HMGB1) promote the proliferation of the T cell immunoglobulin domain and mucin domain protein-1 positive regulatory B (TIM-1+ Breg) cells by inducing the Toll-like receptor/mitogen-activated protein kinase (TLR/MAPK) pathway and the production of IL-10, an immunosuppressive cytokine, thus working against CD8+ T cells through the TLR2/4-MAPK pathway and leading to immune surveillance failure [36] (Figure 1). These findings demonstrate that TDEs are involved in generating an immunosuppressive microenvironment that promotes the progression of solid tumors. In addition, exosomes may also promote tumor progression in hematological cancers. For example, elevated levels of the lncRNA HOX transcript antisense (HOTAIR) can lead to decreased T-lymphocyte proliferation as well as reduced immunoglobulin production and a reversed ratio of CD4+/CD8+ T cell subsets through the Wnt/β-catenin pathway, which may eliminate the immunologic rejection of leukemia cells [37]. Exosomal circRNAs from tumor cells play a crucial role in poor prognosis in cancer [38]; however, few studies have examined their interaction with the immune system. The immunosuppressive role of tumor-secreted exosomes suggests their potential in tumor therapy, as blockage of tumor-secreted exosomes may enhance the antitumor effects of tumor-related T cells and inhibit the silencing of these cells [39]. However, specific immune cell-derived exosomes may also be conducive to tumor development. In colorectal cancer, macrophage-derived exosomes containing miR-21-5p and miR-155-5p can regulate the Brahma-related gene 1 (BRG1) coding sequence to promote the metastasis of cancer cells (Table 1) [40].

3.2. Exosomes, Oxidative Stress, and Inflammation during Tumor Progression. A sustained oxidative stress state may trigger chronic inflammation through activation of inflammatory pathways [41]. During chronic inflammation, slow release of reactive oxygen species (ROS) can cause genetic mutations in nearby cells, promote the proliferation of malignantly transformed cells, and inhibit apoptosis [41, 42]. For example, pancreatic cancer cell-derived exosomes have been shown to regulate STAT3 signaling in monocytes and induce

**Figure 1:** Various effects of tumor-derived exosomes on the immune system and possible associated pathways in the tumor microenvironment.
the expression of arginase and ROS [43]. In contrast, leukemic cell-derived exosomes increase the levels of inflammatory mediators such as TNF-α and IL-10 in macrophages but decrease ROS levels in BMSCs, thus turning the local bone marrow into a leukemia-friendly microenvironment [44]. These results reflect the different ROS states in solid and nonsolid tumors.

Chronic inflammation can initiate cellular activities that contribute to the malignant transformation of cells, particularly DNA damage and genetic instability [45, 46]. TDEs may accelerate tissue damage and inflammation during tumor progression. In pancreatic cancer, macrophages treated with TDEs secreted a greater amount of inflammatory molecules, including IL-6, IL-1β, and TNF-α [47] (Figure 1). Additionally, in oral cancer, monocytes can take up extracellular vesicles, which promote the activation of immune cells such as macrophages, DCs, and granulocytes. A recent report showed that increased levels of the inflammatory cytokine IFN-γ can disrupt the differentiation of MDSCs and thus interfere with antigen presentation in tumors [55]. TDEs may be involved in this process of immune suppression. In a mouse model of glioma, TDEs containing mir-10a and mir-21 can engulf MDSCs and affect their development to produce immunosuppressive molecules [56]. Similarly, mast cells (MCs) can be considered the bridge between inflammation and immunity in the tumor and may participate in angiogenesis and lymphangiogenesis.

### 3.3 Exosomes, Inflammation, and Immunity in the Tumor Microenvironment

Chronic inflammation may act as a negative mediator in tumor immunity through myeloid-derived suppressor cells (MDSCs), which are precursors of immune cells such as macrophages, DCs, and granulocytes. A recent report showed that increased levels of the inflammatory cytokine IFN-γ can disrupt the differentiation of MDSCs and thus interfere with antigen presentation in tumors [55]. TDEs may be involved in this process of immune suppression. In a mouse model of glioma, TDEs containing mir-10a and mir-21 can engulf MDSCs and affect their development to produce immunosuppressive molecules [56]. Similarly, mast cells (MCs) can be considered the bridge between inflammation and immunity in the tumor and may participate in angiogenesis and lymphangiogenesis.

---

**Table 1: Exosome functions in the tumor microenvironment: effects on the tumor, immunity, and inflammation.**

| Tumor type | Exosome content | Exosome origin | Effector cells | Effector components |
|------------|----------------|---------------|----------------|-------------------|
| Melanoma   | miR-RAB27a     | Tumor         | CD4+ T cells   | BCL-2, BCL-xL     |
| LC, breast cancer | /         | Tumor         | CD4+ INF-γ Th1 cells, DCs | /                |
| HNC        | /              | Tumor         | CD8+ T cells   | CD27/CD28, IFN-γ  |
| EOC        | miR-29a-3p, miR-21-5p | Macrophage | Treg/Th17 cells | STAT3 signaling, Treg/Th17 ratios |
| HCC        | HMGB1          | Tumor         | T cells, TIM-1+ Breg cells, CD8+ T cells | TLR/MAPK pathway, IL-10 |
| Leukemia   | IncRNA HOTAIR  | Tumor         | T lymphocytes, CD4+/CD8+ T cells | Wnt/β-catenin axis, Ig |
| CRC        | miR-21-5p, miR-155-5p | Macrophage | Tumor cells | BRG1 |
| PC         | /              | Tumor         | Macrophages    | IL-6, IL-1β, and TNF-α |
| OC         | /              | Tumor         | Monocytes      | NF-xB pathway, IL-6, MMP9 |
| HCC        | IncRNA TUC339  | Tumor         | Macrophages    | Costimulatory molecules |
| CC         | miR-1246       | Tumor         | Macrophages    | TGF-β |
| GC         | /              | Tumor         | Neutrophils    | HMGB1/TLR4/NF-xB |
| PC         | /              | Tumor         | Monocytes      | STAT3 signaling, arginase, ROS |
| Leukemia   | /              | Tumor         | Macrophages, BM-MSCs | TNF-α, IL-10, ROS |
| EC         | Ecrg-4 mRNA    | Tumor         | /              | Inflammation-related genes |
| Breast cancer | Camel milk   | Tumor cells, CD4+ T cells, CD8+ T cells | Tumor cell apoptosis, ROS |
| Glioma     | miR-10a, miR-21 | Tumor         | MDSCs          | ROS, IL-10, TGF-β |
| LC         | KIT            | Mast cell     | Tumor cells    | KIT/SCF pathway |

*Table abbreviations: LC: lung cancer; HNC: head and neck cancer; EOC: epithelial ovarian cancer; CRC: colorectal cancer; EC: esophageal cancer; PC: pancreatic cancer; OC: oral cancer; CC: colon cancer; and GC: gastric cancer. “/” means “not mentioned.”*
3.4. Exosomes and Immune Tolerance. It has been shown that the lncRNA-SNHG14 can enhance the efficiency of trastuzumab in breast cancer by targeting the B-cell lymphoma-2 (BCL-2) mRNA expression of Bcl-2 [61]. Similarly, for melanoma patients miR-1246 to bind to the 3′UTR of caveolin-1 (Cav1) and function through platelet-derived growth factor receptor (PDGFR) tyrosine signaling to inhibit cell proliferation [62]. Amazingly, exosomes could be used as a tool to overcome the problem of drug resistance. A silencing RNA (siRNA-) targeting GRP78 (siGRP78) contained in exosomes from BMCs was able to impede tumor cell proliferation, invasion, and metastasis in HCC [64]. Gene silencing could also be applied to other chemotherapy-tolerant cancers, as long as the genetic mechanism underlying the effects of the exosomes is known.

3.5. Exosomes and EMT. EMT initiates the conversion of malignant tumor epithelial cells to an interstitial phenotype, which can promote invasion and metastasis. A recent study showed that BMSCs in a hypoxic state transferred exosomal miR-193a-3p, miR-210-3p, and miR-5100 to activate signal transducer and activator of transcription 3 (STAT3) signaling in lung cancer cells and also led to an increase in the levels of vimentin and N-cadherin, two mesenchymal markers [65]. These results strongly suggest that TDEs are involved in tumor EMT progression. Pretreatment with TGF-β, an inflammatory cytokine, exosomal-derived lnc-MMP2-2 was shown to promote the expression of matrix metalloproteinase-2 (MMP2), an important EMT marker, to regulate the dissemination of lung cancer cells through the vasculature [66]. This demonstrates the participation of the immune system in EMT. Furthermore, Snail, an EMT transcriptional factor, was shown to activate the M1 macrophage- (M1 MΦ-) M2 macrophage (M2 MΦ) transition by increasing TDEs-miR-21 and transferring TDEs to CD14+ human monocytes, which promotes the advancement of HNC [67]. Therefore, the import of exosomal siRNAs into tumor cells may be an effective tumor gene and immunotherapy method to suppress the expression of target mRNAs [68]. Interestingly, the impact of exosomes on EMT is not completely one-sided. For example, exosomes containing miR-128-3p block EMT by inhibiting the mRNA expression of B-cell-specific Moloney murine leukemia virus integration site 1 (Bmi1) in CRC [69]. Additionally, cancer-associated fibroblasts (CAFs) can secrete exosomes lacking miR-148b that are transferred to endometrial cancer cells (ECCs) and modulate EMT by relieving the suppression of DNA (cytosine-5)-methyltransferase 1 (DNMT1) [70]. miR-155-5p in exosomes derived from gastric cancer cells induced a mesenchymal-like morphological change and increased the levels of E-cadherin and vimentin as well as resistance to paclitaxel, a classical chemotherapy medicine [71]. These studies demonstrate the significance of exosomes in the modulation of gene expression, components of the extracellular matrix, basement membrane remodeling, and tumor chemotherapy (Table 2).

3.6. Exosomes and Tumor Dormancy. Immune-induced tumor dormancy refers to the phenomenon of cell cycle arrest, downregulation of proliferation-related genes, and slowing of metabolism in tumor cells, which is regulated by the immune system. This quiescent state may be reversed through interactions between exosomes and tumor cells. It has been reported that miR-93 and miR-193 act to decrease cyclin D1 and induce quiescence in glioblastoma multiforme (GBM), which leads to a lower percentage of cycling cells [72]. In addition, increased levels of miR-23b in breast cancer cells transferred from exosomes suppressed the expression of MARCKS, which encodes a protein that facilitates cell cycling [73]. However, in the bone marrow of bladder cancer patients, M1 MΦ-derived exosomes may convert quiescent tumor cells into cycling cells through NF-κB, while M2 MΦ-derived exosomes may contribute to dormancy [74]. This finding exhibits the diverse immunoregulatory roles of immune cells during tumor progression (Table 2).

4. Exosomes in Tumor Immunotherapy

4.1. Exosomes and the Immune Checkpoint Protein PD-1. Programmed death-1 (PD-1), which is expressed on the surface of immune cells, and its ligand programmed cell death-1 ligand 1 (PD-L1), which is expressed in various tumor tissues, are significant immunosuppressive molecules, and their interaction can induce T cell apoptosis and inhibit T cell proliferation, promoting tumor progression. Therefore, inhibitors of PD-1 and PD-L1 are ideal antitumor immune sentinel-related drugs. Recent studies have revealed that exosomes may participate in PD-1-related anti- or pro-tumorigenesis effects. The main obstacle to successful immunotherapy is immunosuppression, and the accumulation of MDSCs is the main mechanism of immunosuppression. It has been reported that oral squamous cell carcinoma (OSCC-) derived exosomes can regulate MDSCs through the miR-21/PTEN/PD-L1 pathway and suppress the cytotoxicity of γδ T cells [75]. Chronic lymphocytic leukemia (CLL-) derived exosomes containing the noncoding Y
RNA hY4 can turn monocytes into procarcinogenic cells through Toll-like receptor 7 (TLR7) signaling, and these cells may release tumor-related cytokines such as C-C motif chemokine ligand 2 (CCL2), CCL4, and IL-6 to generate an inflammatory environment and increase the expression of PD-L1 on the surface of tumor cells to induce immune escape [76]. In addition, exosomes can alter the tumor microenvironment by enveloping PD-L1. Theodoraki et al. showed that PD-L1(+) exosomes in the plasma of patients with HNSCC could inhibit the expression of CD69 on CD8+ T cells, which is a signature of activated T cells [77]. In immunotherapy, treatment with dendritic cells pulsed with TDEs in combination with the PD-1 antibody was shown to enhance the effect of sorafenib, leading to an increased number of PD-1+ CD8+ T cells, and was more efficient than sorafenib alone [78]. In addition, plasma-derived exosomes containing PD-L1 mRNA may enhance the efficiency of nivolumab and pembrolizumab for the treatment of melanoma and non-small cell lung cancer (NSCLC) [79]. γδT cell-derived exosomes containing miR-138 have potential as a drug delivery system targeting PD-1 and CTLA-4 in CD8+ T cells to increase their cytotoxicity in OSCC [80]. However, more evidence for the feasibility of TDE use for clinical applications is needed (Table 3).

4.2. Exosomes and Adoptive Cell Transfer. Adoptive cell transfer (ACT) therapy uses effector cells and immune molecules to directly attack tumor cells and is called “passive” immunotherapy. One of the main players in ACT therapy is tumor-infiltrating lymphocytes (TILs). TILs are a group of heterogeneous antitumor lymphocytes present in tumor tissues that include CD8+ T cells, some CD4+ T cells, a small number of B cells, NK cells, macrophages, DCs, MDSCs, and Tregs. Recent studies have shown that exosomes are involved in TIL-related immunotherapy. For example, exosomal 14-3-3 protein zeta (14-3-3ζ) shed from HCC cells can be transferred to TILs and interfere with their antitumorigenic function [81]. In contrast, Li et al. showed that exosomes derived from DCs can boost the proliferation of naive T cells, subsequently increase the number of cytotoxic T lymphocytes (CTLs), and initiate an immune reaction against HCC [82]. In addition, exosomes released by NK cells can function as fuel for the immune killing machines against various tumors, including glioblastoma, melanoma, and other cancers, in a TNF-α- and granzyme B-related manner [83–85]. NK cell-derived exosomes containing miR-186 exert their cytotoxic effects against neuroblastoma by inhibiting the expression of MYCN and TGFBR1 [86]. These findings suggest that immune cell-derived exosomes may contribute

| Function | Tumor | Exosome contents | Exosome origin | Effector |
|----------|-------|-----------------|---------------|---------|
| EMT      | LC    | miR-193a-3p, miR-210-3p, miR-5100 | BMSCs | STAT3 signaling, vimentin, N-cadherin |
|          | LC    | Inc-MMP2-2 | / | MMP2 |
|          | HNC   | miR-21 | Tumor | Snail, CD14+ human monocytes |
|          | CRC   | miR-128-3p | / | Bmi1/E-cadherin, MRp5 |
|          | EC    | Lacking miR-148b | CAFs | DNM1 |
|          | GC    | miR-155-5p | Tumor | E-cadherin, vimentin |
| Tumor dormancy | GBM | miR-93, miR-193 | Tumor | Cyclin D1 |
| Bladder cancer | / | M1 MΦs | NF-κB p65 |
| Breast cancer | miR-23b | BMSCs | MARCKS |

| Tumor type | Exosome contents | Exosome origin | Effector cells | Active components |
|------------|-----------------|---------------|---------------|------------------|
| OSCC       | miR-21          | Tumor         | MDSCs         | PTEN/PD-L1       |
| CLL        | Y RNA hY4       | Tumor         | Monocytes     | TLR7/CCL2, CCL4, IL-6 |
| HNSCC      | PD-L1(+)        | Tumor         | CD8+ T cells  | CD69             |
| HCC        | PD-1 antibody   | Tumor         | DCs           | PD-1+ CD8+ T cells |
|            | miR-138         | γδ T cell     | CD8+ T cells  | PD-1, CTLA-4     |
|            | 14-3-3ζ         | Tumor         | TILs          | Cell proliferation |
|            | /               | DCs           | Naive T cells, CTLs | Cell proliferation |
| Glioblastoma melanoma | / | NK cells | Tumor cells | TNF-α, granzyme B |
| Neuroblastoma | miR-186       | NK cells      | Tumor cells   | MYCN, TGFBR1     |

Tumor-type abbreviations: LC: lung cancer; HNC: head and neck cancer; EC: endometrial cancer; CRC: colorectal cancer; GBM: glioblastoma multiforme; GC: gastric cancer. “/” means “not mentioned”.

Table 2: Exosomes, EMT, and tumor dormancy.

Table 3: Exosomes and immunotherapy.
to immune activation against tumors by functioning as unmanned vehicles (Table 3).

5. Summary and Perspectives

Exosomes are attracting increasing interest owing to their significant heterogeneity and their ability to regulate the tumor immune microenvironment. Specifically, tumor cell-derived exosomes may accelerate tumor progression by enhancing immunosuppression and inflammation, increasing oxidative stress, inducing EMT, and regulating tumor dormancy, which may lead to a poor prognosis. In contrast, specific immune cell-derived exosomes can act as tumor inhibitors, suggesting their immense potential for use in cancer immunotherapy. However, various possible strategies for their use remain to be validated. At the gene level, some ncRNAs, including miRNAs, circRNAs, and IncRNAs, have been suggested to be closely associated with carcinogenesis. Therefore, if an siRNA can be transferred to tumors via exosomes, it may be able to subsequently downregulate target mRNA expression and inhibit tumor invasion [87]. From the perspective of cell therapy, the interactions between immune cells and tumor cells via exosomes may allow us to modulate immune reactions against cancers. For example, overexpression of protective contents in immune cell-secreted exosomes may assist in killing the tumor cell. In addition, exosomes can be used as carriers for gene therapy and immune therapy to deliver specific tumor-related molecules, such as PD-1 [88]. However, one obstacle preventing the widespread use of exosomes in clinical practice is that the yield of exosomes from traditional culture is low. Additionally, the methods used for the separation and purification of exosomes, namely, ultracentrifugation and sucrose density gradient centrifugation, are time-consuming and laborious. Further studies on exosomes and modifications are needed to solve these problems and facilitate the clinical application of exosomes as drug carriers in antitumor immunotherapy.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Tiantian Wang collected the literature and drafted the manuscript. Jie Shen assisted with preparing the figures and tables. Moussa Ide Nasser revised and edited the manuscript. Qingnan He and Mingyi Zhao conceptualized and guaranteed the review. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Acknowledgments

This study was funded by grants from the New Xiangya Talent Project of the Third Xiangya Hospital of Central South University (JY201524).

References

[1] W. Tang, K. Fu, H. Sun, D. Rong, H. Wang, and H. Cao, "circRNA microarray profiling identifies a novel circulating biomarker for detection of gastric cancer," *Molecular Cancer*, vol. 17, no. 1, p. 137, 2018.
[2] F. A. Alzahrani, M. A. El-Magd, A. Abdelfattah-Hassan et al., "Potential effect of exosomes derived from cancer stem cells and MSCs on progression of DEN-induced HCC in rats," *Stem Cells International*, vol. 2018, Article ID 8058979, 17 pages, 2018.
[3] T. Huang, C. Song, L. Zheng, L. Xia, Y. Li, and Y. Zhou, "The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy," *Molecular Cancer*, vol. 18, no. 1, article 62, 2019.
[4] B. Basu and M. K. Ghosh, "Extracellular vesicles in glioma: from diagnosis to therapy," *BioEssays*, vol. 41, no. 7, article 1800245, 2019.
[5] H. Shao, H. Im, C. M. Castro, X. Breakefeld, R. Weissleder, and H. Lee, "New technologies for analysis of extracellular vesicles," *Chemical Reviews*, vol. 118, no. 4, pp. 1917–1950, 2018.
[6] B. T. Pan, K. Teng, C. Wu, M. Adam, and R. M. Johnstone, "Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes," *The Journal of Cell Biology*, vol. 101, no. 3, pp. 942–948, 1985.
[7] M. R. Ward, A. Abadeh, and K. A. Connelly, "Concise review: rational use of mesenchymal stem cells in the treatment of ischemic heart disease," *Stem Cells Translational Medicine*, vol. 7, no. 7, pp. 543–550, 2018.
[8] R. J. Simpson, S. S. Jensen, and J. W. E. Lim, "Proteomic profiling of exosomes: current perspectives," *Proteomics*, vol. 8, no. 19, pp. 4083–4099, 2008.
[9] M. W. Klinker, V. Lizzio, T. J. Reed, D. A. Fox, and S. K. Lundy, "Human B cell-derived lymphoblastoid cell lines constitutively produce Fas ligand and secrete MHCIIFasL, killer exosomes," *Frontiers in Immunology*, vol. 5, p. 144, 2014.
[10] S. Phyu, T. Skotland, N. P. Hessvik et al., "The ether lipid precursor hexadecylglycerol stimulates the release and changes the composition of exosomes derived from PC-3 cells," *The Journal of Biological Chemistry*, vol. 290, no. 7, pp. 4225–4237, 2015.
[11] J. Bergan, T. Skotland, T. Sylvånne, H. Simolin, K. Ekroos, and K. Sandvig, "The ether lipid precursor hexadecylglycerol causes major changes in the lipidome of HEP-2 cells," *PLoS One*, vol. 8, no. 9, article e75904, 2013.
[12] G. N. Shenoy, J. Loyall, C. S. Berenson et al., "Sialic acid-dependent inhibition of T cells by exosomal ganglioside GD3 in ovarian tumor microenvironments," *Journal of Immunology*, vol. 201, no. 12, pp. 3750–3758, 2018.
[13] S. Li, Y. Li, B. Chen et al., "exoRBase: a database of circRNA, IncRNA and mRNA in human blood exosomes," *Nucleic Acids Research*, vol. 46, no. D1, pp. D106–D112, 2018.
[14] L. Huang, X. Zhang, M. Wang et al., "Exosomes from thymic stromal lymphopoietin-activated dendritic cells promote Th2 differentiation through the OX40 ligand," *Pathobiology*, vol. 86, no. 2–3, pp. 111–117, 2019.
[15] C. Li, D. R. Liu, G. G. Li et al., "CD97 promotes gastric cancer cell proliferation and invasion through exosome-mediated MAPK signaling pathway," *World Journal of Gastroenterology*, vol. 21, no. 20, pp. 6215–6228, 2015.
Exosomal regulation of lymphocyte homing to the gut,” *Blood Advances*, vol. 3, no. 1, pp. 1–11, 2019.

17. H. Valadi, K. Ekström, A. Bossios, M. Sjöstrand, J. J. Lee, and J. O. Lötvall, “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells,” *Nature Cell Biology*, vol. 9, no. 6, pp. 654–659, 2007.

18. X. Dai, C. Chen, Q. Yang et al., “Exosomal circRNA_100284 from arsenite-transformed cells, via microRNA-217 regulation of EZH2, is involved in the malignant transformation of human hepatic cells by accelerating the cell cycle and promoting cell proliferation,” *Cell Death & Disease*, vol. 9, no. 5, p. 454, 2018.

19. A. Yoshimura, K. Sawada, K. Nakamura et al., “Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells,” *BMC Cancer*, vol. 18, no. 1, p. 1065, 2018.

20. D. Xu, M. Song, C. Chai et al., “Exosome-encapsulated miR-6089 regulates inflammatory response via targeting TLR4,” *Journal of Cellular Physiology*, vol. 234, no. 2, pp. 1502–1511, 2019.

21. Q. Yang, G. K. Nanayakkara, C. Drummer et al., “Low-intensity ultrasound-induced anti-inflammatory effects are mediated by several new mechanisms including gene induction, immunosuppressor cell proliferation, and enhancement of exosome biogenesis and docking,” *Frontiers in Physiology*, vol. 8, p. 818, 2017.

22. Z. L. Li, L. L. Lv, T. T. Tang et al., “HIF-1α inducing exosomal microRNA-23a expression mediates the cross-talk between tubular epithelial cells and macrophages in tubulointerstitial inflammation,” *Kidney International*, vol. 95, no. 2, pp. 388–404, 2019.

23. S. L. Tung, D. A. Boardman, M. Sen et al., “Regulatory T cell-derived extracellular vesicles modify dendritic cell function,” *Scientific Reports*, vol. 8, no. 1, p. 6065, 2018.

24. S. Balusu, E. van Wonterghem, R. de Rycke et al., “Identification of a novel mechanism of blood-brain communication during peripheral inflammation via choroid plexus-derived extracellular vesicles,” *EMBO Molecular Medicine*, vol. 8, no. 10, pp. 1162–1183, 2016.

25. L. Chen, F. B. Lu, D. Z. Chen et al., “BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis,” *Molecular Immunology*, vol. 93, pp. 38–46, 2018.

26. A. Zhang, G. Wang, L. Jia, T. Su, and L. Zhang, “Exosome-mediated microRNA-138 and vascular endothelial growth factor in endometriosis through inflammation and apoptosis via the nuclear factor-κB signaling pathway,” *International Journal of Molecular Medicine*, vol. 43, no. 1, pp. 358–370, 2018.

27. Z. Li, F. Liu, X. He, X. Yang, F. Shan, and J. Feng, “Exosomes derived from mesenchymal stem cells attenuate inflammation and demyelination of the central nervous system in EAE rats by regulating the polarization of microglia,” *International Immunopharmacology*, vol. 67, pp. 268–280, 2019.

28. X. Li, L. Liu, J. Yang et al., “Exosome derived from human umbilical cord mesenchymal stem cell mediates miR-181c attenuating burn-induced excessive inflammation,” *eBioMedicine*, vol. 8, pp. 72–82, 2016.

29. I. S. Okoye, S. M. Coomes, V. S. Pelly et al., “MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells,” *Immunity*, vol. 41, no. 3, p. 503, 2014.

30. M. Alexander, A. G. Ramstead, K. M. Bauer et al., “Rab27-dependent exosome production inhibits chronic inflammation and enables acute responses to inflammatory stimuli,” *Journal of Immunology*, vol. 199, no. 10, pp. 3559–3570, 2017.

31. Y. G. Chen, M. V. Kim, X. Chen et al., “Sensing self and foreign circular RNAs by intron identity,” *Molecular Cell*, vol. 67, no. 2, pp. 228–238.e5, 2017.

32. J. Zhou, Y. Yang, W. W. Wang et al., “Melanoma-released exosomes directly activate the mitochondrial apoptotic pathway of CD4(+) T cells through their microRNA cargo,” *Experimental Cell Research*, vol. 371, no. 2, pp. 364–371, 2018.

33. Y. Ning, K. Shen, Q. Wu et al., “Tumor exosomes block dendritic cells maturation to decrease the T cell immune response,” *Immunology Letters*, vol. 199, pp. 36–43, 2018.

34. B. T. Maybruck, L. W. Pfannenstiel, M. Diaz-Montero, and B. R. Gastman, “Tumor-derived exosomes induce CD8(+) T cell suppressors,” *Journal for Immunotherapy of Cancer*, vol. 5, no. 1, p. 65, 2017.

35. J. Zhou, X. Li, X. Wu et al., “Exosomes released from tumor-associated macrophages transfer microRNAs that induce a Treg/Th17 cell imbalance in epithelial ovarian cancer,” *Cancer Immunology Research*, vol. 6, no. 12, pp. 1578–1592, 2018.

36. L. Ye, Q. Zhang, Y. Cheng et al., “Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion,” *Journal for Immunotherapy of Cancer*, vol. 6, no. 1, p. 145, 2018.

37. G. J. Li, H. Ding, and D. Miao, “Long-nocoding RNA HOTAIR inhibits immunologic rejection of mouse leukemia cells through activating the Wnt/β-catenin signaling pathway in a mouse model of leukemia,” *Journal of Cellular Physiology*, vol. 234, no. 7, pp. 10386–10396, 2019.

38. H. Zhang, T. Deng, S. Ge et al., “Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7,” *Oncogene*, vol. 38, no. 15, pp. 2844–2859, 2019.

39. G. N. Shenoy, J. Loyall, O. Maguire et al., “Exosomes associated with human ovarian tumors harbor a reversible checkpoint of T-cell responses,” *Cancer Immunology Research*, vol. 6, no. 2, pp. 236–247, 2018.

40. J. Lan, L. Sun, F. Xu et al., “M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer,” *Cancer Research*, vol. 79, no. 1, pp. 146–158, 2019.

41. S. Reuter, S. C. Gupta, M. M. Chaturvedi, and B. B. Aggarwal, “Oxidative stress, inflammation, and cancer: how are they linked?”, *Free Radical Biology & Medicine*, vol. 49, no. 11, pp. 1603–1616, 2010.

42. K. L. Cheung, J. H. Lee, T. O. Khor et al., “Nr2f2 knockout enhances intestinal tumorigenesis in ApoE−/− mice due to attenuation of anti-oxidative stress pathway while potentiates inflammation,” *Molecular Carcinogenesis*, vol. 53, no. 1, pp. 77–84, 2014.

43. N. Javeed, M. P. Gustafson, S. K. Dutta et al., “Immunosuppressive CD14+HLA-DRhi monocytes are elevated in pancreatic cancer and ‘primed’ by tumor-derived exosomes,” *OncoImmunology*, vol. 6, no. 1, article e1250133, 2016.

44. N. Jafarzadeh, Z. Safari, M. Pornour, N. Amirizadeh, M. Forouzandeh Moghadam, and M. Sadeghizadeh, “Alteration
of cellular and immune-related properties of bone marrow mesenchymal stem cells and macrophages by K562 chronic myeloid leukemia cell derived exosomes,” *Journal of Cellular Physiology*, vol. 234, no. 4, pp. 3697–3710, 2019.

[45] M. Cai, R. Shen, L. Song et al., “Bone marrow mesenchymal stem cells (BM-MSCs) improve heart function in swine myocardial infarction model through paracrine effects,” *Scientific Reports*, vol. 6, no. 1, article 28250, 2016.

[46] M. Murata, R. Thanan, N. Ma, and S. Kawanishi, “Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis,” *Journal of Biomedicine & Biotechnology*, vol. 2012, Article ID 623019, 11 pages, 2012.

[47] S. S. Linton, T. Abraham, J. Liao et al., “Tumor-promoting effects of pancreatic cancer cell exosomes on THP-1-derived macrophages,” *PLoS One*, vol. 13, no. 11, article e0206759, 2018.

[48] F. Momen-Heravi and S. Bala, “Extracellular vesicles in oral squamous carcinoma carry oncogenic miRNA profile and reprogram monocyties via NF-kB pathway,” *Oncotarget*, vol. 9, no. 78, pp. 34838–34854, 2018.

[49] X. Li, Y. Lei, M. Wu, and N. Li, “Regulation of macrophage activation and polarization by HCC-derived exosomal IncRNA TUC339,” *International Journal of Molecular Sciences*, vol. 19, no. 10, article 2958, 2018.

[50] T. Cooks, I. S. Pateras, L. M. Jenkins et al., “Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246,” *Nature Communications*, vol. 9, no. 1, p. 771, 2018.

[51] A. Spiegel, M. W. Brooks, S. Houshyar et al., “Neutrophils suppress intratumoral NK cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells,” *Cancer Discovery*, vol. 6, no. 6, pp. 630–649, 2016.

[52] X. Zhang, H. Shi, X. Yuan, P. Jiang, H. Qian, and W. Xu, “Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration,” *Molecular Cancer*, vol. 17, no. 1, p. 146, 2018.

[53] L. Mao, X. Li, S. Gong et al., “Serum exosomes contain ECRG4 miRNA that suppresses tumor growth via inhibition of genes involved in inflammation, cell proliferation, and angiogenesis,” *Cancer Gene Therapy*, vol. 25, no. 9-10, pp. 248–259, 2018.

[54] A. A. Badawy, M. A. El-Magd, and S. A. Alsadrah, “Therapeutic effect of camel milk and its exosomes on MCF7 cells in vitro and in vivo,” *Integrative Cancer Therapies*, vol. 17, no. 4, pp. 1235–1246, 2018.

[55] M. D. Sharma, P. C. Rodriguez, B. H. Koehn et al., “Activation of p53 in immature myeloid precursor cells controls differentiation into Ly6c<sup>−</sup>CD103<sup>+</sup> monocyctic antigen-presenting cells in tumors,” *Immunity*, vol. 48, no. 1, pp. 91–106.e6, 2018.

[56] X. Guo, W. Qiu, Q. Liu et al., “Immunosuppressive effects of hypoxia-induced gloma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten pathways,” *Oncogene*, vol. 37, no. 31, pp. 4239–4259, 2018.

[57] G. Sammarco, G. Varricchi, V. Ferraro et al., “Mast cells, angiogenesis and lymphangiogenesis in human gastric cancer,” *International Journal of Molecular Sciences*, vol. 20, no. 9, p. 2106, 2019.

[58] H. Xiao, C. Lässer, G. Shelke et al., “Mast cell exosomes promote lung adenocarcinoma cell proliferation – role of KIT-stem cell factor signaling,” *Cell Communication and Signaling*, vol. 12, no. 1, p. 64, 2014.

[59] L. Xiong, S. Zhen, Q. Yu, and Z. Gong, “HCV-E2 inhibits hepatocellular carcinoma metastasis by stimulating mast cells to secrete exosomal shuttle miRNAs,” *Oncology Letters*, vol. 14, no. 2, pp. 2141–2146, 2017.

[60] H. Dong, W. Wang, R. Chen et al., “Exosome-mediated transfer of IncRNA-SNHG14 promotes trastuzumab chemoresistance in breast cancer,” *International Journal of Oncology*, vol. 53, no. 3, pp. 1013–1026, 2018.

[61] M. Kang, M. Ren, Y. Li, Y. Fu, M. Deng, and C. Li, “Exosome-mediated transfer of IncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA,” *Journal of Experimental & Clinical Cancer Research*, vol. 37, no. 1, p. 171, 2018.

[62] G. Chen, A. C. Huang, W. Zhang et al., “Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response,” *Nature*, vol. 560, no. 7718, pp. 382–386, 2018.

[63] P. Kanlikilicer, R. Bayraktar, M. Denizli et al., “Exosomal miRNA confers chemoresistance to targeting Cavi1/p-gp/M2-type macrophage axis in ovarian cancer,” *eBioMedicine*, vol. 38, pp. 100–112, 2018.

[64] H. Li, C. Yang, Y. Shi, and L. Zhao, “Exosomes derived from siRNA against GRP78 modified bone-marrow-derived mesenchymal stem cells suppress sorafenib resistance in hepatocellular carcinoma,” *Journal of Nanobiotechnology*, vol. 16, no. 1, article 103, 2018.

[65] X. Zhang, B. Sai, F. Wang et al., “Hypoxic BM-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT,” *Molecular Cancer*, vol. 18, no. 1, p. 40, 2019.

[66] D. M. Wu, S. H. Deng, T. Liu, R. Han, T. Zhang, and Y. Xu, “TGF-β-mediated exosomal Inc-MMP2-2 regulates migration and invasion of lung cancer cells to the vasculature by promoting MMP2 expression,” *Cancer Medicine*, vol. 7, no. 10, pp. 5118–5129, 2018.

[67] C. H. Hsieh, S. K. Tai, and M. H. Yang, “Snail-overexpressing cancer cells promote M2-like polarization of tumor-associated macrophages by delivering MiR-21-abundant exosomes,” *Neoplasia*, vol. 20, no. 8, pp. 775–788, 2018.

[68] C. Wang, L. Chen, Y. Huang et al., “Exosome-delivered TRPP2 siRNA inhibits the epithelial-mesenchymal transition of FaDu cells,” *Oncology Letters*, vol. 17, no. 2, pp. 1953–1961, 2019.

[69] T. Liu, X. Zhang, L. Du et al., “Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer,” *Molecular Cancer*, vol. 18, no. 1, article 43, 2019.

[70] B. L. Li, W. Lu, J. J. Qu, L. Ye, G. Q. Du, and X. P. Wan, “Loss of exosomal miR-148b from cancer-associated fibroblasts promotes endometrial cancer cell invasion and cancer metastasis,” *Journal of Cellular Physiology*, vol. 234, no. 3, pp. 2943–2953, 2018.

[71] M. Wang, R. Qiu, S. Yu et al., “Paclitaxel-resistant gastric cancer MGC-803 cells promote epithelial-to-mesenchymal transition and chemoresistance in paclitaxel-sensitive cells via exosomal delivery of miR-155-5p,” *International Journal of Oncology*, vol. 54, no. 1, pp. 326–338, 2018.

[72] J. L. Munoz, N. D. Walker, S. Mareedu et al., “Cycling quiescence in temozolomide resistant glioblastoma cells is partly explained by microRNA-93 and -193-mediated...
decrease of cyclin D," *Frontiers in Pharmacology*, vol. 10, p. 134, 2019.

[73] M. Ono, N. Kosaka, N. Tominaga et al., "Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells," *Science Signaling*, vol. 7, no. 332, p. ra63, 2014.

[74] N. D. Walker, M. Elias, K. Guiro et al., "Exosomes from differentially activated macrophages influence dormancy or resurgence of breast cancer cells within bone marrow stroma," *Cell Death & Disease*, vol. 10, no. 2, p. 59, 2019.

[75] L. Li, B. Cao, X. Liang et al., "Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral γδ T cell equilibrium via tumor-derived exosomes," *Oncogene*, vol. 38, no. 15, pp. 2830–2843, 2019.

[76] F. Haderk, R. Schulz, M. Iskar et al., "Tumor-derived exosomes modulate PD-L1 expression in monocytes," *Science Immunology*, vol. 2, no. 13, 2017.

[77] M. N. Theodoraki, S. S. Yerneni, T. K. Hoffmann, W. E. Gooding, and T. L. Whiteside, "Clinical significance of PD-L1(+) exosomes in plasma of head and neck cancer patients," *Clinical Cancer Research*, vol. 24, no. 4, pp. 896–905, 2018.

[78] S. Shi, Q. Rao, C. Zhang, X. Zhang, Y. Qin, and Z. Niu, "Dendritic cells pulsed with exosomes in combination with PD-1 antibody increase the efficacy of sorafenib in hepatocellular carcinoma model," *Translational Oncology*, vol. 11, no. 2, pp. 250–258, 2018.

[79] M. Del Re, R. Marconcini, G. Pasquini et al., "PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC," *British Journal of Cancer*, vol. 118, no. 6, pp. 820–824, 2018.

[80] L. Li, S. Lu, X. Liang et al., "γSTDEs: an efficient delivery system for miR-138 with anti-tumoral and immunostimulatory roles on oral squamous cell carcinoma," *Molecular Therapy - Nucleic Acids*, vol. 14, pp. 101–113, 2019.

[81] X. Wang, H. Shen, G. Zhangyuan et al., "14-3-3ζ delivered by hepatocellular carcinoma-derived exosomes impaired antitumor function of tumor-infiltrating T lymphocytes," *Cell Death & Disease*, vol. 9, no. 2, article 159, 2018.

[82] J. Li, S. Huang, Z. Zhou et al., "Exosomes derived from rAAV/ AFP-transfected dendritic cells elicit specific T cell-mediated immune responses against hepatocellular carcinoma," *Cancer Management and Research*, vol. 10, pp. 4945–4957, 2018.

[83] A. Shoae-Hassani, A. A. Hamidieh, M. Behfar, R. Mohseni, S. A. Mortazavi-Tabatabaeei, and S. Agharzadeh, "NK cell-derived exosomes from NK cells previously exposed to neuroblastoma cells augment the antitumor activity of cytokine-activated NK cells," *Journal of Immunotherapy*, vol. 40, no. 7, pp. 265–276, 2017.

[84] L. Zhu, X. J. Li, S. Kalimuthu et al., "Natural killer cell (NK-92MI)-based therapy for pulmonary metastasis of anaplastic thyroid cancer in a nude mouse model," *Frontiers in Immunology*, vol. 8, p. 816, 2017.

[85] L. Zhu, S. Kalimuthu, P. Gangadaran et al., "Exosomes derived from natural killer cells exert therapeutic effect in melanoma," *Theranostics*, vol. 7, no. 10, pp. 2732–2745, 2017.

[86] P. Neviani, P. M. Wise, M. Murtadha et al., "Natural killer-derived exosomal miR-186 inhibits neuroblastoma growth and immune escape mechanisms," *Cancer Research*, vol. 79, no. 6, pp. 1151–1164, 2019.